Donor and transplantation characteristics
| Characteristic . | Value . | n . |
|---|---|---|
| Median age difference between patient and CB donor, y (range) | 4.1 (0.9-30.7) | 142 |
| Median storage time of the CB unit, mo (range) | 3.6 (0-66.5) | 142 |
| Early disease | 3.0 (1.0-53.6) | |
| Intermediate disease | 5.7 (0-66.5) | |
| Advanced disease | 2.8 (0.8-10.4) | |
| Median total nucleated cells at collection, ×108 (range) | 10.8 (1.3-36.3) | 127 |
| Median total nucleated cells/kg at collection, ×107/kg (range) | 5.1 (1.0-34.6) | 126 |
| Median total nucleated cells/kg at infusion, ×107/kg (range) | 4.1 (0.7-34.6) | 141 |
| ABO compatibility | 143 | |
| Compatible, n (%) | 97 (68%) | |
| Minor incompatibility, n (%) | 16 (11%) | |
| Major incompatibility, n (%) | 30 (21%) | |
| Sex matching (CB/patient) | 146 | |
| Male/male or female/female, n (%) | 80 (55%) | |
| Male/female, n (%) | 34 (23%) | |
| Female/male, n (%) | 32 (22%) | |
| Conditioning regimen | 147 | |
| Reduced intensity, n (%) | 4 (3%) | |
| Myeloablative, n (%) | 143 (97%) | |
| With TBI | 72 | |
| With busulfan (or treosulfan)* | 71 | |
| Antithymocyte globulin, n (%) | 11 (8%) | |
| Use of growth factors after RCBT | 125 | |
| None, n (%) | 39 (31%) | |
| G-CSF, n (%) | 78 (62%) | |
| GM-CSF, n (%) | 5 (4%) | |
| G-CSF and GM-CSF, n (%) | 1 (1%) | |
| G-CSF and EPO, n (%) | 2 (2%) | |
| Median day of onset of growth factors after RCBT (range) | Day (day 0-37) | 79 |
| GVHD prophylaxis | 147 | |
| None, n (%) | 3 (2%) | |
| Steroids alone, n (%) | 2 (1%) | |
| Calcineurin inhibitor-based , n (%) | 142 (97%) | |
| CsA alone, n | 104 | |
| CsA + MMF, n | 3 | |
| CsA + MTX, n | 20 | |
| CsA + MTX + steroids, n | 1 | |
| CsA + steroids, n | 13 | |
| Tacrolimus + steroids, n | 1 |
| Characteristic . | Value . | n . |
|---|---|---|
| Median age difference between patient and CB donor, y (range) | 4.1 (0.9-30.7) | 142 |
| Median storage time of the CB unit, mo (range) | 3.6 (0-66.5) | 142 |
| Early disease | 3.0 (1.0-53.6) | |
| Intermediate disease | 5.7 (0-66.5) | |
| Advanced disease | 2.8 (0.8-10.4) | |
| Median total nucleated cells at collection, ×108 (range) | 10.8 (1.3-36.3) | 127 |
| Median total nucleated cells/kg at collection, ×107/kg (range) | 5.1 (1.0-34.6) | 126 |
| Median total nucleated cells/kg at infusion, ×107/kg (range) | 4.1 (0.7-34.6) | 141 |
| ABO compatibility | 143 | |
| Compatible, n (%) | 97 (68%) | |
| Minor incompatibility, n (%) | 16 (11%) | |
| Major incompatibility, n (%) | 30 (21%) | |
| Sex matching (CB/patient) | 146 | |
| Male/male or female/female, n (%) | 80 (55%) | |
| Male/female, n (%) | 34 (23%) | |
| Female/male, n (%) | 32 (22%) | |
| Conditioning regimen | 147 | |
| Reduced intensity, n (%) | 4 (3%) | |
| Myeloablative, n (%) | 143 (97%) | |
| With TBI | 72 | |
| With busulfan (or treosulfan)* | 71 | |
| Antithymocyte globulin, n (%) | 11 (8%) | |
| Use of growth factors after RCBT | 125 | |
| None, n (%) | 39 (31%) | |
| G-CSF, n (%) | 78 (62%) | |
| GM-CSF, n (%) | 5 (4%) | |
| G-CSF and GM-CSF, n (%) | 1 (1%) | |
| G-CSF and EPO, n (%) | 2 (2%) | |
| Median day of onset of growth factors after RCBT (range) | Day (day 0-37) | 79 |
| GVHD prophylaxis | 147 | |
| None, n (%) | 3 (2%) | |
| Steroids alone, n (%) | 2 (1%) | |
| Calcineurin inhibitor-based , n (%) | 142 (97%) | |
| CsA alone, n | 104 | |
| CsA + MMF, n | 3 | |
| CsA + MTX, n | 20 | |
| CsA + MTX + steroids, n | 1 | |
| CsA + steroids, n | 13 | |
| Tacrolimus + steroids, n | 1 |
CB indicates cord blood; TBI, total body irradiation; CSF, colony-stimulating factor; G, granulocyte; GM, granulocyte macrophage; EPO, erythropoietin; CsA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; and RCBT, related cord blood transplantation.
Only 1 patient received treosulfan at a dose of 12 g/m2.